10-Q: Cardio Diagnostics Holdings Reports Q1 2025 Results, Revenue Declines Amid Strategic Shift

Cardio Diagnostics Holdings, Inc. reported a net loss of $1.635 million on revenue of $940 for the quarter ended March 31, 2025, as the company continues to navigate a strategic shift in its commercialization efforts.

Summary

• Cardio Diagnostics Holdings, Inc. reported its financial results for the first quarter of 2025.
• The company experienced a net loss of $1.635 million, compared to a net loss of $4.164 million in the same period last year.
• Revenue decreased significantly to $940 from $15,928 in the first quarter of 2024.
• Operating expenses totaled $1.632 million, a decrease from $4.174 million in the prior year.
• The company is focusing on driving adoption of its clinical solutions among providers, channel partners, and employers.
• A reverse stock split of 1-for-30 was effected on May 12, 2025, to regain compliance with Nasdaq's minimum bid price requirement.
• The company continues to face challenges in generating revenue and may need to raise additional capital to fund operations.
• The company is exploring remediation measures to address a material weakness in its internal control over financial reporting related to inadequate segregation of duties.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has reduced its net loss and operating expenses, revenue has declined significantly, and the company faces ongoing challenges related to Nasdaq compliance and internal controls. The need for additional capital raises also adds uncertainty.

Positives

• The net loss decreased significantly compared to the same period last year, primarily due to a decrease in general and administrative expenses.
• Operating expenses were substantially reduced year-over-year.
• The company is taking steps to address a material weakness in internal control over financial reporting.
• The company successfully executed a reverse stock split to address Nasdaq compliance issues.
• The company is actively working to expand the adoption of its products across key channels.

Negatives

• Revenue decreased significantly compared to the same period last year.
• The company continues to incur net losses.
• The company has identified a material weakness in its internal control over financial reporting.
• The company may need to raise additional capital to fund operations.
• The company is facing long partnership and sales cycles.

Risks

• The company faces the risk of not achieving profitability.
• The company may not be successful in raising additional capital when needed.
• The company's stock price is volatile, which could impact its ability to raise capital.
• The company is subject to potential claims and legal proceedings.
• The company faces the risk of not regaining compliance with Nasdaq listing requirements.
• The company is exposed to risks associated with the regulatory landscape for LDTs.

Future Outlook

The company expects sales and partnership cycles to continue to be long and plans to expand its business operations and increase revenue generation through various strategies, including developing additional products, expanding its evidence portfolio, leveraging CPT PLA codes, and pursuing strategic partnerships and acquisitions.

Industry Context

The company operates in the cardiovascular disease diagnostics market, which is characterized by a shift towards proactive and personalized medicine. Cardio Diagnostics aims to be a leader in this space by leveraging its AI-driven Integrated Genetic-Epigenetic Engine. The company's success depends on its ability to commercialize its products, secure partnerships, and navigate the evolving regulatory landscape for LDTs.

Comparison to Industry Standards

• It is difficult to compare Cardio Diagnostics directly to industry standards due to its unique focus on epigenetics-based clinical tests for cardiovascular disease.
• Companies like Myriad Genetics and Exact Sciences focus on genetic testing for various diseases, but do not have a direct comparable product to Cardio Diagnostics' Epi+Gen CHD or PrecisionCHD tests.
• Other companies in the cardiovascular diagnostics space, such as Boston Scientific and Abbott, primarily focus on medical devices and equipment rather than diagnostic testing.
• Given the limited revenue and ongoing losses, Cardio Diagnostics' financial performance is below industry benchmarks for established diagnostic companies.
• The company's success will depend on its ability to demonstrate the clinical and economic value of its tests and secure reimbursement from payers.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by cost-cutting measures or strategic shifts.
• Customers may experience changes in product offerings or service delivery.
• Suppliers and creditors may be impacted by the company's financial performance.
• The company's success in developing and commercializing its products could benefit patients by improving cardiovascular disease prevention and treatment.

Next Steps

• Develop additional products, including clinical tests for stroke, congestive heart failure and diabetes.
• Expand clinical and health economics evidence portfolio to continue to demonstrate value of products and increase reach.
• Leverage newly awarded CPT PLA codes.
• Expand the adoption of products across key channels, including health systems and self-insured employers, including for HeartRisk, Cardios SaaS product.
• Scale internal operations capabilities with a focus on improving efficiency and reducing cost of goods sold.
• Pursue potential strategic partnership(s) and acquisition(s) of one or more synergistic companies.

Key Dates

Keywords

Cardio Diagnostics, Financial Results, Q1 2025, Reverse Stock Split, Revenue, Net Loss, Operating Expenses, Internal Controls, Nasdaq Compliance, LDTs